Montelukast Viatris

Montelukast, the active ingredient in Montelukast Viatris, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It treats asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children as prescribed by a healthcare professional.

GNH USA supplies Montelukast Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is a leukotriene receptor antagonist used to manage conditions mediated by leukotriene‑driven inflammation.

- Asthma: improves control of chronic asthma and reduces frequency of exacerbations. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal or perennial allergic rhinitis. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during or after physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort or cramping. - Cough: transient, non‑productive cough. - Nausea: occasional feeling of queasiness. - Dizziness: occasional light‑headedness. - Fatigue: mild tiredness.

Serious or Rare Side Effects: - Allergic reactions: rash, urticaria, angioedema. - Mood changes: depression, anxiety, suicidal thoughts. - Hepatic injury: elevated liver enzymes or hepatitis. - Stevens‑Johnson syndrome: severe skin reaction. - Anaphylaxis: rare, life‑threatening hypersensitivity.

When prescribing Montelukast, consider the following safety measures.

- Monitor mood: watch for depression, anxiety or suicidal ideation. - Hypersensitivity: avoid in patients with known allergy to montelukast or excipients. - Hepatic impairment: use caution; adjust if liver function is compromised. - Pregnancy: evaluate risk‑benefit; data are limited. - Renal impairment: consider dose adjustment in severe renal dysfunction. - Store at room temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines; clinical judgement is required.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase montelukast plasma levels. - Phenobarbital: may reduce montelukast effectiveness.

Moderate Interactions (Monitor Closely): - Fluconazole: may modestly raise montelukast concentrations. - Erythromycin: potential for increased exposure. - Carbamazepine: may lower montelukast levels, reducing efficacy.